Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Luciana Griebel advises clients on global acquisitions and divestitures, private equity transactions, and strategic investments.

She regularly represents leading life sciences and technology companies in some of their most important transactions.

Ms. Griebel acts for companies at all stages of development, as well as investors and management teams.

  • Johnson & Johnson in its:
    • sale of the global rights to Compeed® to HRA Pharma;
    • sale of its portfolio of OTC anti-fungal products (Pevaryl®, Fungoral®, Gyno-Pevaryl® and Epi-Pevaryl®) in certain European countries, to Trimb Healthcare AB; and
    • acquisition of XO1 Limited, an asset-centric biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab.
  • Merck in its:
    • €2.1 billion acquisition of Antelliq Group, a leader in digital animal identification, traceability and monitoring solutions, the fastest growing part of the animal health industry; and
    • multi-year global merger integration with Schering-Plough.
  • AstraZeneca in its strategic oncology collaboration with Innate Pharma S.A., including with respect to its acquisition of a nine percent interest in Innate Pharma.
  • Breath Therapeutics B.V. and existing shareholders Gimv, Sofinnova Partners, Gilde Healthcare and founders on the sale of Breath Therapeutics to Zambon for up to a total of €500 million subject to regulatory and sales milestones with an upfront payment of €140 million.
  • Central European Media Enterprises Ltd., a company listed on NASDAQ and the Prague Stock Exchange, in the $262.2 million sale of its broadcast operations in Croatia (“Nova TV”) and in Slovenia (“POP TV”) to a subsidiary of United Group B.V, a private company which is majority owned by U.S. investment firm KKR.
  • The management team on The Foundry’s investment from HgCapital under the terms of which HgCapital assumed majority ownership from The Carlyle Group for an enterprise value of £200 million ($312 million USD). The Foundry is a leading provider of award-winning creative software.
  • Atopix Therapeutics Limited on its sale to Chiesi Farmaceutici S.p.A.
  • Qualcomm Inc. on its £1.56 billion recommended cash offer for CSR plc.
  • Giorgio Armani S.p.A. on a collaboration with a listed Dubai property company for the development of a worldwide chain of Armani hotels and resorts.
  • BenevolentAI on an £80 million equity investment by new and existing investors, including Woodford Investment Management, at a pre-money valuation of £1.4 billion.
  • A syndicate of investors, including Imperial Innovations, Johnson & Johnson Innovation – JJDC, Inc., Cambridge Innovation Capital and Woodford Patient Capital Trust, on their £31.5 million Series A investment in Inivata Limited, a clinical cancer genomics company employing the precision of ctDNA analysis to improve personalized healthcare in oncology.
  • Peel Hunt LLP, in its role as nominated adviser, in connection with two separate placings by Motif Bio plc, a company with securities admitted to trading on AIM.
  • ReNeuron Group plc, a leading clinical stage stem cell therapy company, on a £68.4 million follow-on financing.

Pro Bono

  • An international charitable organization that provides micro financing to the world’s lowest-income entrepreneurs on a range of corporate matters.
  • SolarAid, a charity focused on the development of renewable energy technologies in Africa and South America on a range of corporate matters.
  • Barnardo’s (the UK’s leading children’s charity) on a range of corporate matters.

Previous Experience

  • Secondment to the in house legal department of a global pharmaceutical company.